Premium
Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study
Author(s) -
Mathers M. J.,
Klotz T.,
Roth S.,
Lümmen G.,
Sommer F.
Publication year - 2009
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/j.1439-0272.2008.00910.x
Subject(s) - premature ejaculation , vardenafil , medicine , sertraline , ejaculation , crossover study , erectile dysfunction , gynecology , placebo , psychology , antidepressant , tadalafil , alternative medicine , pathology , hippocampus , psychoanalysis
Summary We investigated safety and efficacy of vardenafil and sertraline in premature ejaculation (PE). Seventy‐two men graded their primary PE on a scale of 0–8 (0 = almost never, 8 = almost always). Intravaginal ejaculatory latency time (IELT) was measured. Patients were included if they scored their PE as 4 or greater and their IELTs were less than 1.30 min. After 6 weeks of behavioural psychosexual therapy, 49 patients still had a PE of 4 or greater and an IELT less than 1.30 min and they were randomised: 6 weeks vardenafil (10 mg) or sertraline (50 mg). After a wash‐out phase for 1 week, medication was changed in a cross‐over design. Initially, all 72 men with PE received behavioural therapy. Twenty‐three men were satisfied with treatment and excluded. The remaining 49 men graded their PE as 5.94 ± 1.6 and IELT was 0.59 min and patients were randomised. Four men discontinued the study. Vardenafil improved PE grading: 2.7 ± 2.1 ( P < 0.01) and IELT increased to 5.01 ± 3.69 ( P < 0.001). PE grading improved 1.92 ± 1.32, ( P < 0.01) and IELT 3.12 ± 1.89 ( P < 0.001) with sertraline. It is concluded that vardenafil and sertraline are useful agents in the pharmacological treatment of PE.